Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Alnylam Begins Rolling Submission of hATTR Amyloidosis Drug for FDA Approval
Rare Daily Staff RNAi therapeutics developer Alnylam Pharmaceuticals said it has begun submission of a rolling Application to the U.S. Food… Continue Reading
Global Genes Rare Disease Stock Index Ends the Week up 1.86 Percent
The Global Genes Rare Disease Stock Index ended the week up 1. 86 percent, outperforming all of the major indices. The tech sector turned… Continue Reading
Sangamo Treats First First Patient in Genome Editing Trial for MPS II
Rare Daily Staff Sangamo Therapeutics said it treated the first patient in the phase 1/2 clinical trial of its experimental in vivo genome… Continue Reading
Ultragenyx Completes Dosing of First Cohort in Study of Gene Therapy in OTC Deficiency
Rare Daily Staff Ultragenyx Pharmaceutical said it has completed patient dosing in the first cohort of three patients enrolled in a phase… Continue Reading
Sobi Initiates Late-Stage Study of Kineret to Treat Still’s Disease
Rare Daily Staff Swedish Orphan Biovitrum said that it has randomized the first patient in its late-stage study of Kineret in the treatment… Continue Reading
Lessons from Pitching Venture Capitalists
Stories abound about plucky entrepreneurs financing their startups, but it’s unusual to get trench-view insights from founders who have… Continue Reading
Rare Leader: Debra Miller, CEO and Founder of Cure Duchenne
Name: Debra Miller Title: CEO and founder Organization: Cure Duchenne Disease focus: Duchenne Muscular Dystrophy Headquarters: Newport… Continue Reading